Vanadium complexes have been previously utilised as potent inhibitors of cysteine based phosphatases (CBPs). Herein, we present the synthesis and characterisation of two new fluorescently labelled vanadyl complexes (14 and 15) with bridged di-picolinic acid ligand.
Introduction
Cysteine based phosphatases (CBPs) are a large family of enzymes that are defined by a cysteine containing motif (CX 5 R) in their active site and include the protein tyrosine phosphatases (PTPs) and inositol lipid phosphatases 1 . While the former counteract the action of tyrosine protein kinases the latter balance inositol lipid kinases. 2, 3 Both play an important role in the regulation of phosphorylation in cells, which in turn impacts cellular signalling and function. 3, 4 Mutation or dysfunction of many members of this family of enzymes have been implicated in a range of diseases including immune and neurodegenerative disorders, cancer, diabetes and obesity, as well as having a role in inflammatory responses. 5, 6 Given the importance of CBPs in disease progression, they are regarded as interesting targets for drug development, with a variety of inhibitors being reported. 5, [7] [8] [9] [10] [11] [12] [13] [14] One subset of these inhibitors are metal ions and their complexes including vanadium, zinc, copper and others, which have shown potent inhibition of PTPs in vitro and in vivo. 11, [15] [16] [17] [18] [19] In particular, a variety of complexes with both vanadium(IV) and vanadium(V) centres have been developed and characterised for their CBP inhibition properties 7, 10, [20] [21] [22] [23] [24] [25] [26] [27] including several examples with picolinic acid and its derivatives as ligands. [28] [29] [30] [31] [32] [33] The potency of these inhibitors against PTPs and lipid phosphatases can be tuned as a function of the ligand, the vanadium coordination number and the oxidation state. For example, the vanadyl complexes V IV O(picolinic acid) 2 and V IV O(3-hydroxypicolinic acid) 2 (1 and 2, Fig.1 ) have been shown to inhibit specific phosphatases at nanomolar concentrations. 29, 31 Using as a starting point vanadyl-picolinate complexes such as 1 and 2, we were interested in developing novel inhibitors for PTPs and lipid phosphatases with improved features. We hypothesised that more robust vanadyl complexes could be obtained by using ligands where the two picolinic acids were covalently linked by an appropriate spacer to yield a tetradentate ligand (Fig. 2) . Furthermore, the linker would offer the potential for further chemical functionalisation, such as allowing addition of a fluorophore to track cellular uptake and localisation of the resulting vanadyl complexes. Thus, herein we report on the synthesis and characterisation of two new fluorescently labelled di-picolinic acid ligands (8 and 13, Fig. 2 ) and the corresponding vanadyl complexes (14 and 15, Fig. 3 ). We demonstrate that addition of the complexes to PTPs and lipid phosphatase leads to inhibition (in the nM range) of the enzymes' activity. We also show by fluorescence microscopy that the complexes are cell permeable. 
Results and Discussion

Synthesis of ligands
The two new tetradentate ligands (8 and 13) were synthesised as shown in Fig. 2 . 5hydroxypicolinic acid methyl ester (3) 34 was reacted with the corresponding Boc-protected di-alcohol (4 or 9) via a Mitsunobu reaction using diethyl azodicarboxylate and triphenylphosphine. In both cases, after initial purification by column chromatography, the products (5 and 10) were obtained as a mixture with triphenylphosphine oxide. Optimisation of chromatographic conditions reduced the amount of triphenylphosphine oxide but it could not be removed completely. The crude materials were used in the de-protection step which, after purification, yielded the corresponding amines 6 and 11 as pure compounds (as confirmed by 1 H NMR spectroscopy and mass spectrometry). The dansyl fluorophore was introduced via sulfonylation under anhydrous conditions in the presence of triethylamine to obtain 7 and 12, which were taken forward to the final step for removal of the methyl protecting groups to give the corresponding ligands 8 and 13. The formation of the desired products was confirmed by 1 H NMR spectroscopy ( Fig. S1 and S2, Supporting Information) through the disappearance of the methyl peaks (at ca. 3.9 ppm); mass spectrometry provided further evidence for the formation of both 8 and 13. Fluorescence emission spectroscopy confirmed the presence of the dansyl fluorophore in both the diethanolamine (8, Fig. S3 Supporting Information) and dipropanolamine (13) linked ligands with emission maxima at 538 nm and 528 nm respectively. 
Synthesis of vanadyl complexes
In order to prepare the vanadyl complexes, the corresponding ligand was dissolved in water (in the presence of NaHCO 3 ) and an aqueous solution of vanadyl sulphate slowly added. A clear change from a yellow solution to a dark green suspension was observed upon addition of VOSO 4 to the ligand. The new vanadyl complexes 14 and 15 were obtained as dark green solids and were characterised by spectroscopic and analytical techniques. MALDI-TOF mass spectrometry showed peaks corresponding to [M+Na] + in each case. The IR spectra of the two complexes shows peaks for the ligand at 1645-1572 cm -1 (which can be assigned to C=O, C=C and C=N) as well as a strong peak at 965 cm -1 and 961 cm -1 (assigned to V=O) for 14 and 15 respectively ( Table 1 ). The formulation and purity of the complexes was confirmed by elemental analyses. Both vanadyl complexes are fluorescent (Table 1) although their emission intensities are lower than those of the corresponding free ligands. 
Phosphatase inhibition assays
In order to characterise the inhibitory potency of 14 and 15, phosphatase inhibition assays against a selection of PTPs (PTP1B, LMW-PTP, VHR and SHP-2see Table 2 for abbreviations) as well as the inositol lipid phosphatase PTEN were carried out employing 3-O-methylfluorescein phosphate (OMFP) as a substrate. 28 As shown in Table 2 compounds 14 and 15 inhibit all PTPs tested in the mid to high nanomolar range, which is consistent with the inhibitory potency previously reported for compound 1 (Fig 1) . 29, 31 The IC 50 value for 14 against LMW-PTP and PTEN is significantly higher than for the other enzymes while complex 15 has a significantly lower IC 50 value for PTP1B than for any other of the tested phosphatases. These observations suggest that the complexes show some selectivity towards certain PTPs compared to others. There also seems to be an effect on the inhibitory properties of the complex on increasing the length of the linker from diethanolamine (14) to dipropanolamine (15) are around two to three fold higher for compound 15 than 14 whereas the IC 50 is reduced against LMW-PTP on increasing linker length. This suggests that varying the linker length could be used as a method to tune selectivity of the complex as the effect differs across the CBPs. As a control, we also carried out the inhibition studies with the free ligands (8 and 13)
using VHR and LMW-PTP as representative examples of the phosphatases. No inhibition was observed up to a 1 μM concentration of the ligand and only minor effects were observed at 10 μM ( Fig. S6 and S7, Supporting Information); this indicates that the free ligand does not contribute to the IC 50 values reported in Table 2 . We also carried out the inhibition studies using VOSO 4 as a control. As can be seen in Table 2 , the inhibitor profile for VOSO 4 did not match with the one observed for compounds 14 and 15. For example, VOSO 4 is more potent against SHP2, but significantly less potent for PTP1B, which is not what one would expect if the complexes are a delivery mechanism for vanadyl itself. Thus, the data suggests that 14 and 15 are not acting simply as a vanadyl delivery vehicle. This notion was explored in more depth using spectroscopy means (see next section). 
Effects of enzyme on the fluorescence of vanadyl complexes
Having shown that the potency of 14, 15 and VOSO 4 for the selected PTPs is close to each other, it was of interest to corroborate the conclusion drawn from the data presented in table 2 . In order to investigate the integrity of the complexes in the enzyme assays, we made use of the dansyl moiety within the ligand in a number of fluorescence spectroscopic studies. Upon coordination of vanadyl to ligands 8 and 13, the emission of the dansyl decreases, which can be employed to monitor the integrity of the complexes while interacting with the enzymes.
Therefore, we first studied whether the fluorescence of the ligand in complex 14 could be recovered by removing the vanadyl from the corresponding complex with EDTA, a strong vanadyl chelator. 23 As can be seen in Figure Taken together these observations imply that the enzyme LMW-PTP binds to the intact complex (as defined by the vanadyl being near the fluorophore-ligand) and in doing so 'protects' the tightly bound complexes from EDTA. However, we cannot rule out the possibility that the vanadyl, while still bound to the ligand, may form new interactions with the enzymes, which would imply that the vanadyl would exchange partially coordination sites between ligand and enzyme. We should also note that the interaction between the vanadium complexes and the Tris buffer used in these studies is unlikely to affect the observations.
Previous studies have shown that such interactions are weak (i.e. high mM). 35 Furthermore, as we have demonstrated in this study, EDTA is required to remove the vanadium centre from the complex (in Tris buffer). Consequently, under the conditions of our studies, Tris is an appropriate buffer. There is considerable evidence suggesting that such complexes act as prodrugs releasing the active vanadium species in biological media. 36 Interestingly our data suggests that, under the conditions used, the vanadium complexes do not break apart completely.
Cellular uptake studies
In order for the complexes 14 and 15 to be utilised as PTPs inhibitors in a cellular environment their ability to be taken up into cells would have to be confirmed. Compound 14
was chosen as a representative complex and thus, NIH3T3 cells were incubated with three different concentrations of 14 (1, 5 and 10 μM) for 24 hours at 37 ºC. The cells were subsequently analysed by fluorescence microscopy. As can be seen in Fig. 6 , the complex (green) is widely taken up by cells. Under these conditions, the complex is localised throughout the cell, but seems to be enriched in some structures within the nucleus and the perinuclear region. This is in agreement with the known subcellular localisation of PTEN and VHR, which are known to be present in the perinuclear region as well as the nuclear compartment. [37] [38] [39] In contrast, other enzymes that might be targeted by 14 are known to localise to the ER/nuclear envelope network (PTP1B), 40 the cytosol and cytoskeletal compartment (LMW-PTP), 41 or the cytosolic localisation (SHP-2). 39 While we cannot rule out the possibility that the observed localisation of 14 is influenced by other cysteine based phosphatases as well, it seems that in the cellular environment 14 is distributed throughout the cell in a pattern that matches the phosphatases it is targeting. 
